Drugs / Azzalure
Azzalure
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04736745 | Feb 2021 → Oct 2022 | — | Ipsen | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT01014871 | Jul 2009 → Apr 2010 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02297503 | Nov 2014 → Dec 2016 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02297516 | Nov 2014 → Mar 2017 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02108158 | Apr → Dec 2014 | — | Galderma R&D | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Evolus, Inc. | Results Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins evolus.com ↗
Jeuveau ® and Dysport ® demonstrated significantly faster visible effects at Day 3 compared to Botox ® and Xeomin ® . |
| 2024-01-19 | Ipsen | Results TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA ipsen.com ↗
Ipsen (Euronext: IPN; ADR: IPSEY) announced today top line results from its real-world AboLiSh study (NCT04050527), presented at the 7th international TOXINS conference in Berlin, Germany. |
| 2022-05-31 | Galderma R&D | Results Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022 galderma.com ↗
Data confirming that Dysport® was consistently efficacious for the treatment of frown lines, was well tolerated and had a fast onset of effect across three trials with high patient satisfaction reported up to 6 months after injection in phase III trials |
| 2020-11-18 | Galderma R&D | Regulatory Galderma launches Dysport® in China for treatment of glabellar lines galderma.com ↗
Dysport® (abobotulinumtoxinA) has received approval from the National Medical Products Administration of China (NMPA), making it the first new muscle relaxant approved for treatment of glabellar lines in China for eight years. |
| 2020-11-17 | Galderma R&D | Results Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA) galderma.com ↗
Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport® at all four doses achieving a composite two grade improvement responder rate than those treated with placebo at one month. |
| 2020-10-09 | Galderma R&D | Results Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting galderma.com ↗
Subjects are highly satisfied with two treatments of abobotulinumtoxinA a year: results from multi-center, year-long, longitudinal study |
| 2020-05-12 | Galderma R&D | Results Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year galderma.com ↗
Top-line results showed that 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients thought the result of the treatment looked natural. |
| 2019-10-24 | Galderma R&D | Results Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies galderma.com ↗
Further, several studies evaluating the company’s neurotoxin portfolio, including patient satisfaction and duration, will be presented during the meeting. |
| 2009-09-21 | Galderma R&D | Regulatory Azzalure ® approved in Spain for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in Spain for aesthetic use in the treatment of glabellar lines |
| 2009-06-26 | Galderma R&D | Regulatory Azzalure ® approved in Germany for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in Germany for aesthetic use in the treatment of glabellar lines |
| 2009-03-30 | Galderma R&D | Regulatory Azzalure ® is approved in France for aesthetic use in the treatment of frown lines galderma.com ↗
This market authorisation for Azzalure ® follows the collective green light from 15 European countries’ Health Authorities received in end January 2009. |
| 2009-03-12 | Galderma R&D | Regulatory Azzalure ® approved in the UK for aesthetic use in the treatment of glabellar lines galderma.com ↗
Azzalure ® approved in the UK for aesthetic use in the treatment of glabellar lines |
| 2009-02-02 | Galderma R&D | Regulatory The Health Authorities of 15 European countries give a collective green light to Azzalure ® galderma.com ↗
The Health Authorities of 15 European countries give a collective green light to Azzalure ® for the treatment of glabellar lines, paving the way for national marketing authorizations. |
All press releases naming this drug 25 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azzalure | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02108158 ↗ |
| Known as | botulinum toxin type A | “botulinum toxin type A” NCT02108158 ↗ |
| Known as | Dysport | “There are two formulations of BoNT-A available: Botox®/Vistabel®, Allergan and Dysport®/Azzalure®, Ipsen - Galderma” NCT01014871 ↗1“Azzalure or Dysport” NCT02297516 ↗ |
| Modality | Protein / enzyme biologic | “Azzalure (botulinum toxin type A), powder for solution for injection” NCT02108158 ↗ |
| Route | Other | “injected locally” NCT04736745 ↗ |